Search Results - therapeutics

HOME SEARCH RSS
53 Results Sort By:
Intradermal/Transdermal GILZ Delivery for Hair Growth
The current state of art: Hair loss, also known as androgenetic alopecia affects roughly 50% of men and 75% of women older than 65 years. In the US, it affects an estimated 50 million men and 30 million women. Current FDA-approved drugs for hair loss include Finasteride and Minoxidil. Problems with current state of art:However, Finasteride, a 5α-reductase...
Published: 12/4/2019   |   Inventor(s): Mahmood Mozaffari, Babak Baban
Keywords(s):  
Category(s): Therapeutics
Topical Application of GILZ Formulation for Wound Healing
The current state of the art:The primary objectives of wound healing include timely wound closure, prompt pain relief, reduced bacteria contamination, and an esthetically acceptable scar. The currently available wound dressings such as semiocclusive, hydrocolloids, and alginates, are used to heal wounds by creating a moist and clean environment to reduce...
Published: 10/15/2019   |   Inventor(s): Mahmood Mozaffari, Babak Baban, Rafik Abdelsayed
Keywords(s):  
Category(s): Therapeutics
Near-IR activated, violet/blue-emitting adhesive liner containing 2-photon, up-converting nanoparticles for dental bonded restorations
Current State of the Art In dental bonded restoration technique, a methacrylate-based semi-viscous agent (liner) is placed on the prepared tooth structure. This liner is exposed to blue or violet light, which enables the liner to bond to the tooth. Following this, the missing tooth structure is filled with glass-filled composite, the top of which is...
Published: 10/11/2019   |   Inventor(s): Frederick Rueggeberg, Marcello Giannini, Rafael Pacheco
Keywords(s):  
Category(s): Therapeutics
Development of an Endothelial Nitric Oxide Synthase Mutant Resistant to Inhibition by Oxidative Stress for the Treatment of Endothelial Dysfunction
Current State of the Art:A major complication of vascular disease is endothelial dysfunction caused by oxidative stress to the vasculature.  Treatment options include surgery, implantation of stints, medications and lifestyle changes.  Currently there are no gene therapy treatments available for endothelial dysfunction.  Available chemical and pharmaceutical...
Published: 8/14/2019   |   Inventor(s): Stephen Black, Ruslan Rafikov
Keywords(s):  
Category(s): Therapeutics
Sulfoglucuronosyl paragloboside regulation in inflammation: use of siRNA and/or antisense oligonucleotide as anti-inflammatories
TECH ID 2011-028 Title: Methods and Compositions for Maintaining Blood-Brain Barrier IntegrityCurrent State of the Art: The BBB tightly regulates access to the brain that prevents large molecule therapy transport. Certain infections and disorders would benefit from allowing controlled access of therapeutics across the BBB including but not limited to...
Published: 8/14/2019   |   Inventor(s): Robert Yu, Somsankar Dasgupta
Keywords(s):  
Category(s): Therapeutics
A Delivery Method for a Gene Correction Reagent in Mammalian Cells Including Hematopoietic and Other Stem Cells
Current State of the Art:Gene therapy involves the use of introducing healthy genes into a patient whose own genes are defective.  In theory, the genes introduced will combine with the patient’s DNA in targeted cells to trigger production of healthy cells.  Gene therapy has become a viable medical treatment option for certain diseases.  Many current...
Published: 8/14/2019   |   Inventor(s): Steffen Meiler, William Dynan
Keywords(s):  
Category(s): Therapeutics
Sphingolipid Metabolite Mimetics Synthesis and Use in Cancer Therapy
Current State of the Art:Lipids are fatty substances found in every cell in our bodies. Sphingolipids are a particular family of lipids which are bioeffectors that mediate various cellular processes. They were discovered in that late 19th century by German biochemist Johann Thudichum who is said to have named them after the sphinx because they were...
Published: 8/13/2019   |   Inventor(s): Kebin Liu, Feiyan Liu, Ping Wu, Zhizhen Huang
Keywords(s):  
Category(s): Therapeutics
Autologous or Allogeneic Mesenchymal Stem Cell Therapy for Premature Ovarian Failure and other forms of ovarian-based female infertility
Premature ovarian failure (POP) is defined as hypergonadotropic ovarian failure occurring prior to age 40. AU researchers used human bone marrow mesenchymal stem cells to reverse infertility in a chemotherapy induced ovarian failure mouse model. The cells were delivered by direct intra-ovarian injection. The treatment were successful with all treated...
Published: 8/13/2019   |   Inventor(s): Ayman Al-Hendy
Keywords(s):  
Category(s): Therapeutics
Manipulation of the p53 pathway as a novel target for cancer immunotherapy
AU researchers have identified a novel population of immunogenic dendritic cells that arise from rapid transdifferentiation of immature myeloid-derived suppressor ceils (MOSCs) in tumors. We have discovered that this DC trans-differentiation step is driven by p53 expressed by the host (not the tumor). Mice with a deletion of p53 in host cells lose exactly...
Published: 8/13/2019   |   Inventor(s): David Munn
Keywords(s):  
Category(s): Therapeutics
Fc receptor targeted and virus-like particle (VLP) based tripartite chimeric vaccine technology
TECH ID 2012-025 Title: Tripartitie Polypeptide Vaccine Vector Current State of the Art: Although traditionally viewed as an anti-infectious preventive measure, vaccine use has expanded to treating non-infectious diseases including cancer. Provenge (Dendreon) is currently the only FDA approved therapeutic vaccine at approximately $95,000 per treatment....
Published: 8/13/2019   |   Inventor(s): Yukai He, David Munn, Yuan Hong
Keywords(s):  
Category(s): Therapeutics
1 2 3 4 5 6 
© 2019. All Rights Reserved. Powered by Inteum